Loading
Life sciences · Journal article
Genome Medicine · October 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that controls energy homeostasis, and impaired GLP-1 secretion or responsiveness is associated with metabolic diseases. Much effort has been made to develop long-lasting GLP-1-based therapeutics, whereas frequently associated with drug resistance and side effects. GLP-1 is predominantly released postprandially by enteroendocrine cells, while programmable GLP-1 delivery is rarely explored. Herein, genetically engineered probiotic bacteria for diet-induced programmable GLP-1 delivery were developed. The therapeutic efficacy of diet-induced and constitutive GLP-1 delivery was compared in a murine model of obesity, followed by microbiome profiling and functional characterization of gut bacterial GLP-1-degrading enzymes. In murine model of obesity, the anti-adiposity and anti-steatosis effects of diet-induced programmable GLP-1 delivery by synthetic bacteria were greater than that of microbial persistent GLP-1 delivery. Notably, genes encoding microbe-derived GLP-1 peptidase isoenzymes were discovered in gut bacteria specifically enriched by persistent GLP-1 delivery in murine and clinical studies, while diet-induced GLP-1 delivery minimized the abundance of these gut bacteria with GLP-1 inactivation potential. Our findings provide insights into host-microbiome-therapeutic interactions, and highlight programmable delivery strategies for peptide-based therapeutics.